Clinical Trials Logo

Clinical Trial Summary

This is a prospective multicenter phase II trial of gemcitabine, cisplatin, and ifosfamide (GIP) in patients with relapsed non-seminomatous germ-cell tumors (NSGCT) and a predicted favorable prognosis.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00127049
Study type Interventional
Source Gustave Roussy, Cancer Campus, Grand Paris
Contact Karim FIZAZI, Dr
Phone 33 1 42114559
Email fizazi@igr.fr
Status Recruiting
Phase Phase 2
Start date December 2004

See also
  Status Clinical Trial Phase
Recruiting NCT06133543 - Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer N/A
Terminated NCT00369291 - CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant Phase 1
Terminated NCT00198172 - Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors Phase 2
Recruiting NCT05874063 - Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors Phase 3
Completed NCT03194906 - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Phase 2
Completed NCT01466231 - Everolimus in Refractory Testicular Germ Cell Cancer Phase 2
Recruiting NCT04791228 - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Phase 2
Active, not recruiting NCT03418844 - Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy N/A
Recruiting NCT05889585 - Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated With High-dose Chemotherapy and Autologous Stem Cell Transplant
Recruiting NCT05394675 - A Study of DS-9606a in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT03067181 - Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Phase 3
Withdrawn NCT03960151 - Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy Phase 2
Active, not recruiting NCT03158064 - Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Phase 2
Completed NCT03950830 - Disulfiram and Cisplatin in Refractory TGCTs. Phase 2
Recruiting NCT00898755 - Collecting and Storing Tissue From Young Patients With Cancer
Recruiting NCT04804007 - Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT Phase 2
Terminated NCT02988843 - Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors Phase 2
Recruiting NCT05259605 - Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Active, not recruiting NCT03638167 - EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors Phase 1
Recruiting NCT04308330 - Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies Phase 1